Literature DB >> 19748118

NPY regulation of bone remodelling.

Nicola J Lee1, Herbert Herzog.   

Abstract

Neuropeptide Y (NPY), a classic neuronal regulator of energy homeostasis, is now also known to be involved in the control of bone homeostasis. Of the five known Y receptors through which the NPY family of ligands signals, the Y1 and Y2 receptors have so far been implicated in the control of osteoblast activity and thus bone formation. Analysis of brain specific NPY overexpressing and Y receptor knockout models has revealed a powerful anabolic pathway likely involving hypothalamic Y2 receptors and osteoblastic Y1 receptors. Furthering our understanding of the mechanisms underlying the involvement of the NPY system in the control of bone could lead to the development of therapies to improve bone mass in patients with diseases such as osteoporosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19748118     DOI: 10.1016/j.npep.2009.08.006

Source DB:  PubMed          Journal:  Neuropeptides        ISSN: 0143-4179            Impact factor:   3.286


  31 in total

1.  Neuropeptide Y receptor interactions regulate its mitogenic activity.

Authors:  Magdalena Czarnecka; Congyi Lu; Jennifer Pons; Induja Maheswaran; Pawel Ciborowski; Lihua Zhang; Amrita Cheema; Joanna Kitlinska
Journal:  Neuropeptides       Date:  2018-11-27       Impact factor: 3.286

2.  Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.

Authors:  Eugen Kloster; Carsten Saft; Denis A Akkad; Jörg T Epplen; Larissa Arning
Journal:  J Mol Med (Berl)       Date:  2014-02       Impact factor: 4.599

Review 3.  Roles of leptin in bone metabolism and bone diseases.

Authors:  Xu Xu Chen; Tianfu Yang
Journal:  J Bone Miner Metab       Date:  2015-03-18       Impact factor: 2.626

Review 4.  Niche heterogeneity in the bone marrow.

Authors:  Alexander Birbrair; Paul S Frenette
Journal:  Ann N Y Acad Sci       Date:  2016-03-25       Impact factor: 5.691

5.  Extracellular norepinephrine clearance by the norepinephrine transporter is required for skeletal homeostasis.

Authors:  Yun Ma; Jessica J Krueger; Sara N Redmon; Sasidhar Uppuganti; Jeffry S Nyman; Maureen K Hahn; Florent Elefteriou
Journal:  J Biol Chem       Date:  2013-09-04       Impact factor: 5.157

6.  Orexin regulates bone remodeling via a dominant positive central action and a subordinate negative peripheral action.

Authors:  Wei Wei; Toshiyuki Motoike; Jing Y Krzeszinski; Zixue Jin; Xian-Jin Xie; Paul C Dechow; Masashi Yanagisawa; Yihong Wan
Journal:  Cell Metab       Date:  2014-05-01       Impact factor: 27.287

7.  Systemic levels of neuropeptide Y and dipeptidyl peptidase activity in patients with Ewing sarcoma--associations with tumor phenotype and survival.

Authors:  Jason U Tilan; Mark Krailo; Donald A Barkauskas; Susana Galli; Haifa Mtaweh; Jessica Long; Hongkun Wang; Kirsten Hawkins; Congyi Lu; Dima Jeha; Ewa Izycka-Swieszewska; Elizabeth R Lawlor; Jeffrey A Toretsky; Joanna B Kitlinska
Journal:  Cancer       Date:  2014-11-11       Impact factor: 6.860

Review 8.  Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family.

Authors:  Itai Bab; Reem Smoum; Heather Bradshaw; Raphael Mechoulam
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

9.  Neuropeptide Y regulates the hematopoietic stem cell microenvironment and prevents nerve injury in the bone marrow.

Authors:  Min Hee Park; Hee Kyung Jin; Woo-Kie Min; Won Woo Lee; Jeong Eun Lee; Haruhiko Akiyama; Herbert Herzog; Grigori N Enikolopov; Edward H Schuchman; Jae-sung Bae
Journal:  EMBO J       Date:  2015-04-27       Impact factor: 11.598

Review 10.  Neuropeptide Y (NPY) in tumor growth and progression: Lessons learned from pediatric oncology.

Authors:  Jason Tilan; Joanna Kitlinska
Journal:  Neuropeptides       Date:  2015-10-26       Impact factor: 3.286

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.